Maricarmen Tapia-Venancio, Dirección de Educación e Investigación en Salud, Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Hospital de Especialidades de Puebla, Instituto Mexicano del Seguro Social (IMSS) Puebla, México
Ernesto Hernández-Jiménez, Departamento de Cardiología, Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Hospital de Especialidades de Puebla, Instituto Mexicano del Seguro Social (IMSS) Puebla, México
Arturo García-Galicia, Unidad Médica de Alta Especialidad Hospital de Especialidades de Puebla, Dirección de Educación e Investigación en Salud, Centro Médico Nacional General de División Manuel Ávila Camacho, Instituto Mexicano del Seguro Social (IMSS). Puebla, México
Diana López-García, Directorate of Education and Research in Health, High Speciality Medical Unit, Specialties Hospital of Puebla,Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla of Zaragoza, Puebla, Mexico
Anali Durán-Cordero, Departamento de Medicina Interna. Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Hospital de Especialidades de Puebla, Instituto Mexicano del Seguro Social (IMSS) Puebla, México
Edgar Bautista-Soto, Dirección de Educación e Investigación en Salud, Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Hospital de Especialidades de Puebla, Instituto Mexicano del Seguro Social (IMSS) Puebla, México
Álvaro J. Montiel-Jarquín, Dirección de Educación e Investigación en Salud, Centro Médico Nacional Gral. de Div. Manuel Ávila Camacho, Hospital de Especialidades de Puebla, Instituto Mexicano del Seguro Social (IMSS) Puebla, México
Adriana Hernández-Carrasco, Facultad de Medicina, Universidad Popular Autónoma del Estado de Puebla, H. Puebla de Zaragoza. Puebla, Pue., México
Jorge Loria-Castellanos, Coordinación de Proyectos Especiales en Salud, IMSS, Ciudad de México, México
Background: Heart failure (HF) is a clinical syndrome that is usually the final consequence of pre-existing heart disease; the use of sacubitril-valsartan is intended to reduce mortality and improve quality of life (QoL). Objective: To compare the QoL in patients with HF with reduced ventricular ejection fraction (LVEF) before and after treatment with sacubitril-valsartan. Material and methods: Comparative, longitudinal, prospective study in HF patients with reduced LVEF who started treatment with sacubitril/valsartan. The Minnesota questionnaire for quality of life in patients with heart failure (MLHFQ) was administered before and three months after treatment with sacubitril/valsartan. Data analysis was performed with descriptive statistics and Student’s t test for related samples. Results: A total of 103 patients were enrolled in the study, with a predominance of male sex and ischemic heart disease as the etiology. Beta-blockers were the most common concomitant treatment at 91.3%. The most frequent initial and final dose of sacubitril-valsartan administered was 24/26 mg every 12 hours. The previous and subsequent mean MLHFQ total dimension scores were 47 (± 17) and 43 (± 16) respectively (p < 0.05). Conclusions: Patients with reduced LVEF HF treated with sacubitril-valsartan improve their QoL at three months of management.
Keywords: Quality of life. Heart failure. Sacubitril/valsartan. Ventricular dysfunction.